In Brief: Auragen
This article was originally published in The Gray Sheet
Executive Summary
Auragen: W.R. Grace & Co. subsidiary awarded $960,000 three-year research grant from U.S. Army Medical Research and Material Command's Breast Cancer Research Program to evaluate its Accell gene therapy system for breast cancer. The grant allows the Middleton, Wisconsin-based firm to evaluate the therapeutic potential of using the gene gun device to cutaneously deliver the interleukin-12 gene for mammary tumor therapy in animal models...
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.